Early Prediction of Oral Cancer by S100A7 Immunohistochemistry Signature-based Assessment
Recruiting now NCT04622462
Run by Proteocyte Diagnostics Inc. · for 15 to 90 · All sexes
What this study is about
The purpose of this observational study is to evaluate the utility of the S100A7 immunohistochemistry signature-based assessment - STRATICYTE - in determining the risk of progression to cancer of clinically suspicious oral lesions.
Who can join (things the study team will check)
✅ You may be able to join if…
- Any clinically suspicious lesion biopsied to rule-out oral epithelial dysplasia/oral squamous cell carcinoma
🚫 You may not be able to join if…
- Biopsied lesion with or without dysplasia concomitant with oral squamous cell carcinoma at initial biopsy
Where this trial is running
- Kingsway Oral & Maxillofacial Surgery, Edmonton, Alberta, Canada
- University of Alberta, Edmonton, Alberta, Canada
- Western University, London, Ontario, Canada
Who to contact
Jason Hwang, PhD · (647) 255-1370 · jhwang@proteocyte.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04622462.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.